On March 28, the Food and Drug Administration approved Pluvicto, a new radiation agent able to treat patients with prostate cancer. Just six days later, James ...
Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback